glp 1 agonists for type 2 diabetes GLP-1 receptor are increasingly used to treat and obesity, and trials have shown reductions in cardiovascular risk and slowing of kidney failure. Adverse events are mostly gastrointestinal. Read Upcoming wave of hormone-based therapies

The new biology and pharmacology of glucagon

especially since the intrinsic hypoglycaemia risk of DPP-4 inhibitors is very low

GLP-1 increases insulin and decreases glucagon levels, which will result in decreased blood glucose [8, 9]

When President Trumps team of negotiators got Eli Lilly and Novo Nordisk to agree to a monthly $245 price in Medicare and Medicaid in November, that price was supposed to be for all GLP-1s, including those for obesity, which until then had not been covered by Medicare

Overexpression of insulin receptor substrate 1 (IRS1) relates to poor prognosis and promotes proliferation, stemness, migration, and oxidative stress resistance in cholangiocarcinoma

January 2, 2023